Juthaporn Cowan profile picture

Contact Information

Juthaporn Cowan, MD, PhD, FRCPC
(613)737-8899 ext. 79617

Administrative Coordinator:
Andrea Angelo

ORCID logo https://orcid.org/0000-0001-6648-5109

Juthaporn Cowan

Associate Scientist, Inflammation & Chronic Disease
Ottawa Hospital Research Institute
Associate Professor, Department of Medicine, Division of Infectious Diseases
University of Ottawa
Assistant Professor, Department of Biochemistry, Microbiology, and Immunology
University of Ottawa

Research Interests

  • Prevention of infections in non-HIV immunodeficiency particularly post-transplantation
  • Vaccination in immunocompromised patients
  • Immunotherapy for primary and secondary immunodeficiency diseases
  • Cellular and molecular immunology of infectious diseases
  • Microbial pathogenesis and host immune defence mechanism 

Brief Biography

Juthaporn Cowan is an Associate Scientist at The Ottawa Hospital Research Institute, Associate Professor at The University of Ottawa, Division of Infectious Diseases, Department of Medicine and Department of Biochemistry, Microbiology, and Immunology. She is an Infectious Diseases physician at The Ottawa Hospital.

Dr. Cowan began her training at Mahidol University in Thailand for her MD. She also obtained a PhD in Microbiology and Immunology at Kyoto University in Kyoto, Japan. She completed a Postdoctoral Fellowship at The Ottawa Hospital Research Institute. Her research at the time focused on Tuberculosis and immunopathogenesis. She then started her Internal Medicine training at the University of Ottawa. During her postgraduate training her interest shifted from tuberculosis to infection in immunodeficiency patients. Subsequently, she completed a Clinical Fellowship in Infectious Diseases with the University of Ottawa.

Drs. D. William Cameron and Cowan run an immunodeficiency/immunoglobulin treatment clinic at the Ottawa Hospital. The clinic is expanding and is served as a resource for clinical research. Dr. Cowan is the medical lead for the Ontario Immunoglobulin Treatment Program (ONIT). The ONIT Program is a Ministry of Ontario approved initiative to improve the healthcare of patients with immunodeficiencies requiring immunoglobulin replacement therapy. This clinical program is set out to support immunoglobulin replacement therapy through home, self-administered subcutaneous immunoglobulin (SCIG) infusion. That Support is provided through hospital-based outpatient clinics with nursing coordination. The main objectives of the program are to provide consistent, standardised diagnosis and management of immunodeficiencies requiring immunoglobulin treatment. The ONIT Program currently has 4 centers: The Ottawa Hospital, St. Michael’s Hospital, Hamilton Health Sciences and Sault Area Hospital.

Selected Publications

Abadeh, A., Shehadeh, S., Betschel, S., Waserman, S., Cameron, DW., Cowan, J. (2023). Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry. PLOS ONE. 18(11):e0294408. Doi: https://doi.org/10.1371/journal.pone.0294408

Mir, A., Ivory, C., Cowan, J. (2023). Concurrence of Familial Mediterranean fever and Behçet's disease: A case report and review. Journal of Medical Case Reports.17:438. Doi: https://doi.org/10.1186/s13256-023-04185-5

Pratt, AJ., Purssell, A., Zhang, T., Luks, VPJ., Bauza, X., Mulpuru, S., Kirby, M., Aaron, SD., Cowan, J. (2023). Complexity in clinical diagnoses of acute exacerbation of chronic obstructive pulmonary disease. BMC Pulmonary Medicine, 23(1):298. Doi: https://doi.org/10.1186/s12890-023-02587-1

Cowan, J., Amson, A., Christofides, A., Chaga, Z. (2023). Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations. International Journal of Infectious Diseases. 134(Sept):228-238. Doi: 10.1016/j.ijid.2023.06.021

Milne, K.M., Cowan, J., Schaeffer, M.R., Voduc, N., Corrales-Medina, V., Lavoie, K.L., Chirinos, J.A., Puyat, J.H., Abdallah, S.J., Guenette, J.A. (2023). Exercise responses and mental health symptoms in COVID-19 survivors with dyspnoea. ERJ Open Research. 9(3):1-42. Doi: 10.1183/23120541.00606-2022

Diseases, conditions and populations of interest

Research and clinical approaches